<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 03 Mar 2021 16:20:30 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>艾力斯三代EGFR-TKI甲磺酸伏美替尼获NMPA批准上市</title><link>https://mp.weixin.qq.com/s/jreYeNXpNqFbQqS3S5D6zg</link><description></description><content:encoded><![CDATA[艾力斯三代EGFR-TKI甲磺酸伏美替尼获NMPA批准上市]]></content:encoded><pubDate>Wed, 03 Mar 2021 14:47:30 +0800</pubDate></item><item><title>SMO抑制剂上市申请获CDE优先审评，治疗基底细胞癌</title><link>https://mp.weixin.qq.com/s/3pfFBLVGZlEGrdtSu28s1w</link><description></description><content:encoded><![CDATA[SMO抑制剂上市申请获CDE优先审评，治疗基底细胞癌]]></content:encoded><pubDate>Wed, 03 Mar 2021 14:47:30 +0800</pubDate></item><item><title>国内首个！思路迪AXL抑制剂申报临床</title><link>https://mp.weixin.qq.com/s/pAlMrcYCSv59gMKDkZ_IOg</link><description></description><content:encoded><![CDATA[国内首个！思路迪AXL抑制剂申报临床]]></content:encoded><pubDate>Wed, 03 Mar 2021 14:47:30 +0800</pubDate></item><item><title>信达生物国清院热招中【We Are Hiring】Principal Investigators and Scientists</title><link>https://mp.weixin.qq.com/s/M2sxwprueZj-o-4NtLsg_g</link><description></description><content:encoded><![CDATA[信达生物国清院热招中【We Are Hiring】Principal Investigators and Scientists]]></content:encoded><pubDate>Wed, 03 Mar 2021 14:47:30 +0800</pubDate></item><item><title>默沙东在美国自主撤回Keytruda治疗转移性小细胞肺癌适应症</title><link>https://mp.weixin.qq.com/s/hePFMpXez1DF5uIf1XBmPw</link><description></description><content:encoded><![CDATA[默沙东在美国自主撤回Keytruda治疗转移性小细胞肺癌适应症]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:43:40 +0800</pubDate></item><item><title>中国本土Pharma，如何转型创新才能真正赚钱？</title><link>https://mp.weixin.qq.com/s/W9Pt6ZQzW8noz6dv6N9cuw</link><description></description><content:encoded><![CDATA[中国本土Pharma，如何转型创新才能真正赚钱？]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:43:40 +0800</pubDate></item><item><title>普利制药「注射用比伐卢定」美国专利挑战成功！</title><link>https://mp.weixin.qq.com/s/strOsHNp-xpirhndl7sXzg</link><description></description><content:encoded><![CDATA[普利制药「注射用比伐卢定」美国专利挑战成功！]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:43:40 +0800</pubDate></item><item><title>贝达药业PI3Kα抑制剂获批临床</title><link>https://mp.weixin.qq.com/s/IdSlKw6Z-p__Da-rV74M1Q</link><description></description><content:encoded><![CDATA[贝达药业PI3Kα抑制剂获批临床]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:43:40 +0800</pubDate></item><item><title>再鼎2020年财报：尼拉帕利收入2.2亿元</title><link>https://mp.weixin.qq.com/s/tUbVt0zxyb95GCEhtwT_mg</link><description></description><content:encoded><![CDATA[再鼎2020年财报：尼拉帕利收入2.2亿元]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:43:40 +0800</pubDate></item><item><title>Inovio宣布DNA免疫疗法治疗宫颈癌变创新药首个III期临床成功</title><link>https://mp.weixin.qq.com/s/6S3bwsMlCsUEZ-gZBc8gWQ</link><description></description><content:encoded><![CDATA[Inovio宣布DNA免疫疗法治疗宫颈癌变创新药首个III期临床成功]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:43:40 +0800</pubDate></item><item><title>新版医保目录今日执行！78个谈判品种价格信息公开</title><link>https://mp.weixin.qq.com/s/-W2nVpEdhGZ-STFRbA2c5w</link><description></description><content:encoded><![CDATA[新版医保目录今日执行！78个谈判品种价格信息公开]]></content:encoded><pubDate>Mon, 01 Mar 2021 16:17:03 +0800</pubDate></item><item><title>2021年2月，FDA批准的8款新药</title><link>https://mp.weixin.qq.com/s/fBzvhqFwJAJ2-4fVKm51Ng</link><description></description><content:encoded><![CDATA[2021年2月，FDA批准的8款新药]]></content:encoded><pubDate>Mon, 01 Mar 2021 16:17:03 +0800</pubDate></item><item><title>恒瑞一海外公司CEO加盟诺诚健华担任CMO</title><link>https://mp.weixin.qq.com/s/Jp4dw3R3UFU0mzc7IoYN5g</link><description></description><content:encoded><![CDATA[恒瑞一海外公司CEO加盟诺诚健华担任CMO]]></content:encoded><pubDate>Mon, 01 Mar 2021 16:17:03 +0800</pubDate></item><item><title>医药魔方核心行业数据监测周报（2月20-26日）</title><link>https://mp.weixin.qq.com/s/GL2bf-qYvgyv-T-xmb-TRw</link><description></description><content:encoded><![CDATA[医药魔方核心行业数据监测周报（2月20-26日）]]></content:encoded><pubDate>Mon, 01 Mar 2021 16:17:03 +0800</pubDate></item><item><title>君实生物与阿斯利康签署特瑞普利单抗独家推广协议</title><link>https://mp.weixin.qq.com/s/-UyMSJriT5b0jJQVFA_Piw</link><description></description><content:encoded><![CDATA[君实生物与阿斯利康签署特瑞普利单抗独家推广协议]]></content:encoded><pubDate>Sun, 28 Feb 2021 17:20:26 +0800</pubDate></item><item><title>Sarepta公司第3款反义寡核苷酸疗法获FDA批准上市</title><link>https://mp.weixin.qq.com/s/IGN2Faek-I_uc2uZTjt-HQ</link><description></description><content:encoded><![CDATA[Sarepta公司第3款反义寡核苷酸疗法获FDA批准上市]]></content:encoded><pubDate>Fri, 26 Feb 2021 18:10:55 +0800</pubDate></item><item><title>甲状腺癌死亡风险降低78%！多靶点TKI抑制剂获FDA突破性疗法认定</title><link>https://mp.weixin.qq.com/s/rGPbceP0NA3wMH80kHooyw</link><description></description><content:encoded><![CDATA[甲状腺癌死亡风险降低78%！多靶点TKI抑制剂获FDA突破性疗法认定]]></content:encoded><pubDate>Fri, 26 Feb 2021 18:10:55 +0800</pubDate></item><item><title>辉瑞/BioNTech 疫苗获FDA批准可在正常冷冻温度下保存2周</title><link>https://mp.weixin.qq.com/s/iVataB4EsDWSbGb9atfILw</link><description></description><content:encoded><![CDATA[辉瑞/BioNTech 疫苗获FDA批准可在正常冷冻温度下保存2周]]></content:encoded><pubDate>Fri, 26 Feb 2021 18:10:55 +0800</pubDate></item><item><title>超10亿大品种！齐鲁「唑来膦酸注射液」通过一致性评价</title><link>https://mp.weixin.qq.com/s/RUyKABEwhEw71WXfuDW5fg</link><description></description><content:encoded><![CDATA[超10亿大品种！齐鲁「唑来膦酸注射液」通过一致性评价]]></content:encoded><pubDate>Fri, 26 Feb 2021 18:10:55 +0800</pubDate></item><item><title>百奥泰2020业绩快报：阿达木单抗销售收入1.83亿元</title><link>https://mp.weixin.qq.com/s/8FqxIak_Jh5V-isS-jAaxw</link><description></description><content:encoded><![CDATA[百奥泰2020业绩快报：阿达木单抗销售收入1.83亿元]]></content:encoded><pubDate>Fri, 26 Feb 2021 18:10:55 +0800</pubDate></item></channel></rss>